Your browser doesn't support javascript.
loading
Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future.
Subbiah, Ishwaria M; Gonzalez-Angulo, Ana Maria.
Afiliação
  • Subbiah IM; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4009, USA.
Curr Treat Options Oncol ; 15(1): 41-54, 2014 Mar.
Article em En | MEDLINE | ID: mdl-24323591
OPINION STATEMENT: The natural history of HER2-positive breast cancer significantly changed in the past 15 years. Form being the most aggressive type of breast cancer, it became treatable with important cure rates. However, with new and successful drugs, resistance emerges. Progress in research and drug development continues to make available effective anti-HER2 therapies. Our challenge today is to use these tools correctly by looking at the data that support the indications of each compound and to continue clinical trial participation.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Anticorpos Monoclonais / Antineoplásicos Limite: Female / Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Anticorpos Monoclonais / Antineoplásicos Limite: Female / Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article